Drug Trial Radar · NCT05586074
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Mar 3, 2023
Primary completion
Nov 30, 2027
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.
Conditions
- Leukemia, Acute Myeloid (AML)
Interventions
ClifutinibDrug
tablet, oral
LoDACDrug
subcutaneous (SC) or intravenous (IV) injection
AzacitidineDrug
SC or IV
DecitabineDrug
IV
Ara-C±IDADrug
SC and IV
FLAG-IDADrug
SC and IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: From the date of randomization until the date of death from any cause, assessed up to 5 years
- CR/CRh rateTime frame: From randomization until the data cut-off date of April 2025, all subjects included in the primary analysis of CR/CRh rate were followed up at least 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital,College of Medicine,Zhejiang University
Hanzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.